J. Michael Berry-Lawhorn

Dr. J. Michael Berry-Lawhorn


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
NJNaomi Jay
Naomi Jay
RCRoss D. Cranston
Ross D. Cranston
TDTeresa M. Darragh
Teresa M. Darragh
EHElizabeth A. Holly
Elizabeth A. Holly
JPJoel M. Palefsky
Joel M. Palefsky
The incidence of anal cancer is elevated in human immunodeficiency virus (HIV)‐infected men‐who‐have‐sex‐with‐men (MSM) compared to the general population. Anal high‐grade squamous intraepithelial lesions (HSIL) are common in HIV‐infected MSM and the presumed precursors to anal squamous cell cancer; however, direct progression of HSIL to anal cancer has not been previously demonstrated. The medical records were reviewed of 138 HIV‐infected MSM followed up at the University of California, San Francisco, who developed anal canal or perianal squamous cancer between 1997 and 2011. Men were followed up regularly with digital anorectal examination (DARE), high‐resolution anoscopy (HRA) and HRA‐guided biopsy. Although treatment for HSIL and follow‐up were recommended, not all were treated and some were lost to follow‐up. Prevalent cancer was found in 66 men. Seventy‐two HIV‐infected MSM developed anal cancer while under observation. In 27 men, anal cancer developed at a previously biopsied site of HSIL. An additional 45 men were not analyzed in this analysis due to inadequate documentation of HSIL in relation to cancer location. Of the 27 men with documented progression to cancer at the site of biopsy‐proven HSIL, 20 men progressed from prevalent HSIL identified when first examined and seven men from incident HSIL. Prevalent HSIL progressed to cancer over an average of 57 months compared to 64 months for incident HSIL. Most men were asymptomatic, and cancers were detected by DARE. Anal HSIL has clear potential to progress to anal cancer in HIV‐infected MSM. Early diagnosis is facilitated by careful follow‐up. Carefully controlled studies evaluating efficacy of screening for and treatment of HSIL to prevent anal cancer are needed.

1 February 2009 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
JPJoel M. Palefsky
Joel M. Palefsky
NJNaomi Jay
Naomi Jay
SCSu-Chun Cheng
Su-Chun Cheng
TDTeresa M. Darragh
Teresa M. Darragh
PCPeter V. Chin-Hong
Peter V. Chin-Hong
High-resolution anoscopy is colposcopy of the anus after applying 3 percent acetic acid. High-resolution anoscopy with biopsy was used as the standard for detecting high-grade anal neoplasia and was compared to detection of high-grade anal neoplasia by anal cytology, human papillomavirus testing, or the combination. A total of 125 men who have sex with men (MSM) were enrolled from a group of MSM identified by random digit dialing: HIV-negative = 85, HIV-positive = 35, and unknown status = 5. A specimen was taken for anal cytology and human papillomavirus testing, followed by high-resolution anoscopy with biopsy of any lesions. Ninety-one percent of HIV-positive and 57 percent of HIV-negative MSM had anal human papillomavirus infection. In HIV-positive men the sensitivity of abnormal cytology to detect high-grade anal neoplasia was 87 percent, and in HIV-negative MSM it was 55 percent. Among HIV-negative men, 9 of 20 cases of high-grade anal neoplasia would have been missed because cytology was negative, but the addition of human papillomavirus positivity increased sensitivity for the combination to 90 percent. Sensitivity and specificity of anal cytology and human papillomavirus testing are different in HIV-positive and HIV-negative MSM for detecting high-grade anal neoplasia when patients have high-resolution anoscopy-guided biopsy of lesions. The optimum use of human papillomavirus testing has yet to be defined. High-resolution anoscopy is an effective tool for diagnosing high-grade anal neoplasia.

10 January 2022 in Contemporary Clinical Trials
Verified
Journal Article
Open access
JLJeannette Y. Lee
Jeannette Y. Lee
SLShelly Y. Lensing
Shelly Y. Lensing
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
NJNaomi Jay
Naomi Jay
TDTeresa M. Darragh
Teresa M. Darragh
JPJoel Palefsky
Joel Palefsky
It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high as 14.1% among PLWH compared with 3.2% among those who are not living with HIV.

20 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SCSona Chowdhury
Sona Chowdhury
TDTeresa M. Darragh
Teresa M. Darragh
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
MIMaria Isaguliants
Maria Isaguliants
VMVonsky S Maxim
Vonsky S Maxim
JPJoel Palefsky
Joel Palefsky
The incidence of anal cancer is increasing, especially in high-risk groups, such as PLWH. HPV 16, a high-risk (HR) HPV genotype, is the most common genotype in anal high-grade squamous intraepithelial lesions (HSIL) and squamous cell carcinoma (SCC) in the general population. However, few studies have described the distribution of HR HPV genotypes other than HPV 16 in the anus of PLWH. HPV genotyping was performed by DNA amplification followed by dot-blot hybridization to identify the HR and low-risk (LR) genotypes in benign anal lesions (n = 34), HSIL (n = 30), and SCC (n = 51) of PLWH and HIV-negative individuals. HPV 16 was the most prominent HR HPV identified, but it was less common in HSIL and SCC from PLWH compared with HIV-negative individuals, and other non-HPV 16 HR HPV (non-16 HR HPV) types were more prevalent in samples from PLWH. A higher proportion of clinically normal tissues from PLWH were positive for one or more HPV genotypes. Multiple HPV infection was a hallmark feature for all tissues (benign, HSIL, SCC) of PLWH. These results indicate that the development of anal screening approaches based on HPV DNA testing need to include non-16 HR HPVs along with HPV 16, especially for PLWH. Along with anal cytology, these updated screening approaches may help to identify and prevent anal disease progression in PLWH.


1 April 2014 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JBJ. Michael Berry-Lawhorn
J. Michael Berry-Lawhorn
DCDaniel Chrobak
Daniel Chrobak
NJNaomi Jay
Naomi Jay
JPJoel M. Palefsky
Joel M. Palefsky